乐普生物再现“黑马”

医药魔方Info
Nov 07, 2025

乐普生物带来的“惊喜”仍在继续。继全球首个EGFR ADC在实体瘤领域成功获批,奠定了里程碑般的成就后,血液瘤领域又杀出一匹“黑马”——靶向CD20的ADC药物MRG001,其联合BTK抑制剂奥布替尼治疗复发/难治性弥漫大B细胞淋巴瘤(R/R DLBCL)的II期临床数据在第67届美国血液学协会(ASH)年会上惊艳亮相,把市场的预期一再拉高。支撑这份高预期的,首先是MRG001在复发/难治...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10